Pyrazolo compounds and methods of use thereof
US-12110276-B2 · Oct 8, 2024 · US
Vitamin D3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound
US12473310B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12473310-B2 |
| Application number | US-202118031836-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2021 |
| Priority date | Oct 20, 2020 |
| Publication date | Nov 18, 2025 |
| Grant date | Nov 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is the compound vitamin D 3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound. Also disclosed are methods of treating vitamin D deficiency using the compound. The compound is particularly suitable for transdermal delivery.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein the compound is more than 80% pure. 2 . The compound of claim 1 , wherein the compound is of the formula (IA): or a pharmaceutically acceptable salt thereof. 3 . The compound according to claim 2 , wherein the compound is in the free acid form. 4 . The compound according to claim 2 , wherein the compound is in the form of a pharmaceutically acceptable salt. 5 . A compound of the formula (I): wherein the compound is in the form of a di-sodium salt the compound is more than 80% pure. 6 . A compound of formula (IA): wherein the compound is in the form of a di-sodium salt the compound is more than 80% pure.
Assignees
Inventors
Classifications
Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation · CPC title
containing P(=O)-halide groups · CPC title
Drugs for dermatological disorders · CPC title
- C07F9/095Primary
Compounds containing the structure P(=O)-O-acyl, P(=O)-O-heteroatom, P(=O)-O-CN · CPC title
- C07F9/117Primary
with cycloaliphatic alcohols · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12473310B2 cover?
- Disclosed is the compound vitamin D 3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound. Also disclosed are methods of treating vitamin D deficiency using the compound. The compound is particularly suitable for transdermal delivery.
- Who is the assignee on this patent?
- King S College London
- What technology area does this patent fall under?
- Primary CPC classification C07F9/095. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).